Ozmosi | AT-GTX-701 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

AT-GTX-701

Alternative Names: AT-GTX-701, ATGTX701
Clinical Status: Active
Latest Update: 2021-02-08
Latest Update Note: News Article

Product Description

AT-GTX-701 is a preclinical drug candidate being developed by Amicus for the treatment of Fabry Disease. (Sourced from: https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-presents-positive-preclinical-fabry-disease)

Mechanisms of Action: Gene Therapy, GLA

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amicus
Company Location: Eastern America
Company Founding Year: 2002
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Fabry Disease

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

02/08/2021

News Article

 Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions